[Register here](https://events.techinmotion.com/fireside-chat-c-light-technologies/meetup) to join the discussion!

Whether you’re a founder, aspiring entrepreneur, investor, or startup enthusiast, this fireside chat series will provide you with honest, insightful looks into how our community of visionaries is building life-changing products and companies.

During this session, we’ll hear from the minds behind **C. Light Technologies**, the award-winning neuro-tech and AI startup revolutionizing the way we detect, monitor, and treat Alzheimer’s, MS, and other central nervous system conditions.

Founders Dr. Christy Sheehy and Dr. Joe Xing will share each step of their startup journey, from developing a novel technology, raising funding, to building their team and so much more. Don’t miss this opportunity to talk shop, and get the insights you need to be successful in this industry.

**Discussion Topics**:

* Roadmap for a Tech Founder
* Advice for Raising Startup Capital
* How to Build & Sustain a Talent Engine
* C. Light Technologies Revolutionizing Retinal Eye-Tracking Technology
* Scaling your Startup & Setting Future Goals

**Who You’ll Hear From:**

* **Adam O’Donnell**, Event Host | Startups Partnerships @ Zendesk
* **Dr. Christy Sheehy**, CEO & Founder @ C. Light Technologies
* **Dr. Joe Xing**, CTO & Co-founder @ C. Light Technologies

**About C. Light Technologies**
Boston-based C. Light Technologies, Inc. is a neurotech and artificial intelligence company that tracks retinal (back of the eye/front of brain) movements less than 1/100th of a human hair. With their own proprietary scanning laser ophthalmoscope–the “Retitrack”–C. Light analyzes miniature eye movements with AI, a very different approach to eye tracking from other technologies on the market which measure pupil movement. C. Light’s device is 120x more accurate than pupil trackers sold commercially today and 1000x more than webcams and phone cameras. The scan takes 10 seconds with no dilation or patient discomfort required.

C. Light’s biomarker platform could transform how we assess neurological diseases such as Alzheimer’s and multiple sclerosis, as well as brain injuries such as concussions, allowing for early detection (when more treatment options could be available), and more objective ways to measure if therapies are working or not.